Amedeo Smart

Free Medical Literature Service

 

Amedeo

Antiretroviral Therapy
  Free Subscription

Articles published in
J Acquir Immune Defic Syndr
    April 2024
  1. DORWARD J, Sookrajh Y, Lessells R, Bulo E, et al
    Viremia and HIV Drug Resistance Among People Receiving Dolutegravir Versus Efavirenz-Based First-Line Antiretroviral Therapy.
    J Acquir Immune Defic Syndr. 2024;95:e8-e11.
    >> Share

    March 2024
  2. QIAN Y, Zhang P, Wang L, Suo J, et al
    The association of intraocular efavirenz concentrations and HIV-1 viral load among persons with HIV.
    J Acquir Immune Defic Syndr. 2024 Mar 25. doi: 10.1097/QAI.0000000000003426.
    >> Share

  3. VAN HEERDEN JK, Meintjes G, Barr D, Zhao Y, et al
    Relationship Between Tenofovir Diphosphate Concentrations in Dried Blood Spots and Virological Outcomes After Initiating Tenofovir-Lamivudine-Dolutegravir as First-Line or Second-Line Antiretroviral Therapy.
    J Acquir Immune Defic Syndr. 2024;95:260-267.
    >> Share

    February 2024
  4. GRIESEL R, Banda CG, Zhao Y, Omar Z, et al
    PHARMACOKINETICS OF SINGLE VERSUS DOUBLE-DOSE DOLUTEGRAVIR AFTER SWITCHING FROM A FAILING EFAVIRENZ-BASED REGIMEN.
    J Acquir Immune Defic Syndr. 2024 Feb 15. doi: 10.1097/QAI.0000000000003402.
    >> Share

  5. DE WIT S, Bonnet F, Osiyemi O, Bisshop F, et al
    Durable Efficacy of Switching From a 3- or 4-Drug Tenofovir Alafenamide-Based Regimen to the 2-Drug Regimen Dolutegravir/Lamivudine in the TANGO Study Through Week 196.
    J Acquir Immune Defic Syndr. 2024 Feb 8. doi: 10.1097/QAI.0000000000003395.
    >> Share

    January 2024
  6. TURK T, Labarile M, Braun DL, Rauch A, et al
    CHARACTERIZATION AND DETERMINANTS OF LONG-TERM IMMUNE RECOVERY UNDER SUPPRESSIVE ANTIRETROVIRAL THERAPY.
    J Acquir Immune Defic Syndr. 2024 Jan 24. doi: 10.1097/QAI.0000000000003388.
    >> Share

  7. BUNGE K, Balkus JE, Fairlie L, Mayo AJ, et al
    DELIVER: A Safety Study of a Dapivirine Vaginal Ring and Oral PrEP for the Prevention of HIV During Pregnancy.
    J Acquir Immune Defic Syndr. 2024;95:65-73.
    >> Share

    December 2023
  8. BROOKS KM, Pau AK, Swaim D, Bunn HT, et al
    Pharmacokinetics, Safety, and Tolerability of Once-Daily Darunavir With Cobicistat and Weekly Isoniazid/Rifapentine.
    J Acquir Immune Defic Syndr. 2023;94:468-473.
    >> Share

  9. FAIRLIE L, Sawry S, Pals S, Sherman G, et al
    More Frequent HIV Viral Load Testing With Point-Of-Care Tests Detects Elevated Viral Load Earlier in Postpartum HIV-Positive Women in a Randomized Controlled Trial in Two Clinics in Johannesburg, South Africa.
    J Acquir Immune Defic Syndr. 2023;94:412-420.
    >> Share

  10. HECHTER RC, Zhou H, Leyden WA, Yuan Q, et al
    Fracture Risk and Association With TDF Use Among People With HIV in Large Integrated Health Systems.
    J Acquir Immune Defic Syndr. 2023;94:341-348.
    >> Share

    November 2023
  11. ARNOLD EM, Kamal S, Rotheram-Borus MJ, Bridges SK, et al
    Factors Associated with Antiretroviral Adherence among Youth Living with HIV.
    J Acquir Immune Defic Syndr. 2023 Nov 17. doi: 10.1097/QAI.0000000000003345.
    >> Share

  12. LIEGEON G, Brun A, Hamet G, Zeggagh J, et al
    Incidence and Management of Complex Kidney Situations Among On-demand and Daily HIV Pre-exposure Prophylaxis Users.
    J Acquir Immune Defic Syndr. 2023 Nov 16. doi: 10.1097/QAI.0000000000003346.
    >> Share

  13. JIANG W, Ronen K, Osborn L, Drake AL, et al
    HIV viral load patterns and risk factors among women in prevention of mother-to-child transmission (PMTCT) programs to inform differentiated service delivery (DSD).
    J Acquir Immune Defic Syndr. 2023 Nov 15. doi: 10.1097/QAI.0000000000003352.
    >> Share

  14. LANTING VR, Oosterhof P, Moha DA, van Heerde R, et al
    Switching to doravirine in cART experienced patients: An effective and highly tolerated option with substantial cost savings.
    J Acquir Immune Defic Syndr. 2023 Nov 10. doi: 10.1097/QAI.0000000000003337.
    >> Share

  15. BOUSMAH MA, Protopopescu C, Mpoudi-Etame M, Omgba Bassega P, et al
    Improvements in Patient-Reported Outcomes Following Initiation of Dolutegravir-Based or Low-Dose Efavirenz-Based First-Line Antiretroviral Therapy: A Four-Year Longitudinal Analysis in Cameroon (NAMSAL ANRS 12313 Trial).
    J Acquir Immune Defic Syndr. 2023;94:262-272.
    >> Share

  16. FERNVIK E, Sierra Madero J, Espinosa N, Gulminetti R, et al
    Impact of Treatment Adherence on Efficacy of Dolutegravir + Lamivudine and Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Week 144 Analysis of the GEMINI-1 and GEMINI-2 Clinical Studies.
    J Acquir Immune Defic Syndr. 2023;94:e9-e12.
    >> Share

    October 2023
  17. KATAREY D, Tan Y, Mourad A, Potts JR, et al
    Non-viral Liver Disease Burden in People Living with HIV and elevated transaminases: A Cross-sectional Study.
    J Acquir Immune Defic Syndr. 2023 Oct 12. doi: 10.1097/QAI.0000000000003322.
    >> Share

    September 2023
  18. GEIGER K, Patil A, Budhathoki C, Dooley KE, et al
    Successful MDR-TB Treatment Without HIV Viral Suppression: A Missed Opportunity.
    J Acquir Immune Defic Syndr. 2023 Sep 28. doi: 10.1097/QAI.0000000000003268.
    >> Share

  19. CHI BH, Saidi F, Graybill LA, Phanga T, et al
    A patient-centered, combination intervention to support adherence to HIV pre-exposure prophylaxis during pregnancy and breastfeeding: a randomized pilot study in Malawi.
    J Acquir Immune Defic Syndr. 2023 Sep 28. doi: 10.1097/QAI.0000000000003309.
    >> Share

  20. POLISENO M, Mazzitelli M, Narducci A, Ferrara SM, et al
    Doravirine plus Integrase Strand Transfer Inhibitors as a two-drugs treatment-switch strategy in PLWH: the real-life DORINI multicentric cohort study.
    J Acquir Immune Defic Syndr. 2023 Sep 27. doi: 10.1097/QAI.0000000000003248.
    >> Share

  21. BUNGE K, Balkus JE, Fairlie L, Mayo AJ, et al
    DELIVER: A Safety Study of a Dapivirine Vaginal Ring and Oral PrEP for the Prevention of HIV During Pregnancy.
    J Acquir Immune Defic Syndr. 2023 Sep 27. doi: 10.1097/QAI.0000000000003312.
    >> Share

    August 2023
  22. BOUSMAH MA, Protopopescu C, Mpoudi-Etame M, Bassega PO, et al
    Improvements in patient-reported outcomes following initiation of dolutegravir- or low-dose efavirenz-based first-line antiretroviral therapy: A four-year longitudinal analysis in Cameroon (NAMSAL ANRS 12313 trial).
    J Acquir Immune Defic Syndr. 2023 Aug 14. doi: 10.1097/QAI.0000000000003273.
    >> Share

    June 2023
  23. REIS AO, Rocco Suassuna JH, Cunha CB, Portela EN, et al
    Evaluation of glomerular filtration rate trends in people living with HIV corrected by the baseline glomerular filtration rate.
    J Acquir Immune Defic Syndr. 2023 Jun 1. doi: 10.1097/QAI.0000000000003232.
    >> Share

    May 2023
  24. VHEMBO T, Baltrusaitis K, Tierney C, Owor M, et al
    Bone and renal health in infants with or without breastmilk exposure to tenofovir-based maternal antiretroviral treatment in the PROMISE randomized trial.
    J Acquir Immune Defic Syndr. 2023 May 15. doi: 10.1097/QAI.0000000000003218.
    >> Share

    April 2023
  25. DORWARD J, Sookrajh Y, Lessells R, Bulo E, et al
    Point-of-care viral load testing to manage HIV viraemia during the rollout of dolutegravir-based ART in South Africa: a randomised feasibility study (POwER).
    J Acquir Immune Defic Syndr. 2023 Apr 19. doi: 10.1097/QAI.0000000000003212.
    >> Share

    March 2023
  26. JENNINGS L, Ferraris CM, Castillo-Mancilla JR, Robbins RN, et al
    Comparing predictive ability of two objective adherence measures in a community-based cohort on antiretroviral therapy in South Africa: tenofovir diphosphate concentrations and electronic adherence monitors.
    J Acquir Immune Defic Syndr. 2023 Mar 27. doi: 10.1097/QAI.0000000000003198.
    >> Share

  27. QIAN Y, Wang L, Xing Y, Yin L, et al
    Tenofovir concentration is not enough in intraocular tissues of patients with HIV-infection.
    J Acquir Immune Defic Syndr. 2023 Mar 1. doi: 10.1097/QAI.0000000000003171.
    >> Share

    February 2023
  28. ELBUR AI, Ghebremichael M, Konkle-Parker D, Jones DL, et al
    Trajectories of Antiretroviral Therapy Adherence and Virologic Failure in Women with HIV in the United States.
    J Acquir Immune Defic Syndr. 2023 Feb 20. doi: 10.1097/QAI.0000000000003174.
    >> Share

  29. HICKEY MD, Wafula E, Ogachi SM, Ojwando H, et al
    Weight change following switch to dolutegravir for HIV treatment in rural Kenya during country roll-out.
    J Acquir Immune Defic Syndr. 2023 Feb 14. doi: 10.1097/QAI.0000000000003173.
    >> Share

  30. VAN PRAET JT, Serrien B, Ausselet N, Darcis G, et al
    Dynamics of weight change after initiation of contemporaneous antiretroviral therapy in treatment-naive HIV-1 patients: results from the Belgian HIV Cohort 2015-2021.
    J Acquir Immune Defic Syndr. 2023 Feb 14. doi: 10.1097/QAI.0000000000003175.
    >> Share

  31. JACOBS TG, Mumbiro V, Chitsamatanga M, Namuziya N, et al
    Suboptimal lopinavir exposure in infants on rifampicin treatment receiving double-dosed or semi-superboosted lopinavir/ritonavir: time for a change.
    J Acquir Immune Defic Syndr. 2023 Feb 1. doi: 10.1097/QAI.0000000000003168.
    >> Share

    January 2023
  32. KEENE CM, Cassidy T, Zhao Y, Griesel R, et al
    Recycling tenofovir in second-line antiretroviral treatment with dolutegravir: outcomes and viral load trajectories to 72 weeks.
    J Acquir Immune Defic Syndr. 2023 Jan 25. doi: 10.1097/QAI.0000000000003157.
    >> Share

  33. CHAPIN-BARDALES J, Haaland R, Martin A, Holder A, et al
    HIV pre-exposure prophylaxis persistence and adherence among men who have sex with men in 4 U.S. cities.
    J Acquir Immune Defic Syndr. 2023 Jan 9. doi: 10.1097/QAI.0000000000003160.
    >> Share

  34. GANESAN K, Mwesigwa R, Dear N, Esber AL, et al
    EPIDEMIOLOGY OF TUBERCULOSIS AMONG PEOPLE LIVING WITH HIV IN THE AFRICAN COHORT STUDY FROM 2013-2021.
    J Acquir Immune Defic Syndr. 2023 Jan 3. doi: 10.1097/QAI.0000000000003152.
    >> Share

    December 2022

  35. Efficacy and Safety of a Simplified Lamivudine Plus Dolutegravir Dual Therapy in HIV-1-Infected Patients: A Multicenter Cohort Study in China: Erratum.
    J Acquir Immune Defic Syndr. 2022;91:516.
    >> Share

  36. AJIBOLA G, Maswabi K, Hughes MD, Bennett K, et al
    Long-term clinical, immunologic, and virologic outcomes among early-treated children with HIV in Botswana: a nonrandomized controlled clinical trial.
    J Acquir Immune Defic Syndr. 2022 Dec 12. doi: 10.1097/QAI.0000000000003147.
    >> Share

  37. SAROWAR A, Coffin CS, Fung S, Wong A, et al
    Brief Report: Effect of Antiretroviral Switch From Tenofovir Disoproxil fumarate to Tenofovir Alafenamide on Alanine Aminotransferase, Lipid Profiles, and Renal Function in HIV/HBV-Coinfected Individuals in a Nationwide Canadian Study.
    J Acquir Immune Defic Syndr. 2022;91:368-372.
    >> Share

    November 2022
  38. MILLER AP, Shoptaw S, Moucheraud C, Mvududu R, et al
    Recent alcohol use is associated with increased Pre-exposure Prophylaxis (PrEP) continuation and adherence among pregnant and post-partum women in South Africa.
    J Acquir Immune Defic Syndr. 2022 Nov 21. doi: 10.1097/QAI.0000000000003133.
    >> Share

  39. PIERRE DE VILLARTAY J, Pannier E, Sibiude J, Frange P, et al
    T Cell Receptor alpha repertoire diversity at birth after in utero exposure to HIV integrase strand-transfer inhibitors.
    J Acquir Immune Defic Syndr. 2022 Nov 7. pii: 00126334-990000000-00149.
    >> Share

    October 2022
  40. COLEMAN JS, Diniz CP, Fuchs EJ, Marzinke MA, et al
    Interaction of Depot Medroxyprogesterone Acetate and Tenofovir Disoproxil Fumarate/Emtricitabine on Peripheral Blood Mononuclear Cells and Cervical Tissue Susceptibility to HIV Infection and Pharmacokinetics.
    J Acquir Immune Defic Syndr. 2022 Oct 13. pii: 00126334-990000000-00134.
    >> Share

  41. MELVIN AJ, Yee KL, Gray KP, Yedla M, et al
    Pharmacokinetics, tolerability and safety of doravirine and doravirine/lamivudine/tenofovir disoproxil fumarate fixed dose combination tablets in adolescents living with HIV: Week 24 results from IMPAACT 2014.
    J Acquir Immune Defic Syndr. 2022 Oct 10. pii: 00126334-990000000-00136.
    >> Share

  42. ZHONG M, Chen C, Hu Y, Zou M, et al
    Efficacy and Safety of a Simplified Lamivudine Plus Dolutegravir Dual Therapy in HIV-1-Infected Patients: A Multicenter Cohort Study in China.
    J Acquir Immune Defic Syndr. 2022;91.
    >> Share

  43. YAN D, Wang Z, Wang Y, He S, et al
    Performance of Creatinine- and Cystatin C-Based Equations for Glomerular Filtration Rate Estimation in HIV-1-Infected Individuals Receiving Dolutegravir + Tenofovir Disoproxil Fumarate + Lamivudine as Initial Antiretroviral Therapy: A Retrospective Ob
    J Acquir Immune Defic Syndr. 2022;91.
    >> Share

  44. ZHAO F, Rao M, Chen W, Cai K, et al
    Dolutegravir Plus Lamivudine Dual-Drug Regimen in Treatment-Naive HIV-1-Infected Patients With High-Level Viral Load: Preliminary Data From the Real World.
    J Acquir Immune Defic Syndr. 2022;91.
    >> Share

  45. SUN L, He Y, Xu L, Zhao F, et al
    Higher Risk of Dyslipidemia With Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide than Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate Among Antiretroviral-Naive People Living With HIV in China.
    J Acquir Immune Defic Syndr. 2022;91.
    >> Share

  46. TONGTONG Y, Shenghua H, Yin W, Lin C, et al
    Effectiveness and Safety of Dolutegravir Versus Efavirenz-Based Antiviral Regimen in People Living With HIV-1 in Sichuan Province of China: A Real-World Study.
    J Acquir Immune Defic Syndr. 2022;91.
    >> Share

  47. DUMCHEV K, Kiriazova T, Riabokon S, Shost A, et al
    Comparative Clinical Outcomes With Scale-up of Dolutegravir as First-Line Antiretroviral Therapy in Ukraine.
    J Acquir Immune Defic Syndr. 2022;91:197-209.
    >> Share

    September 2022
  48. NEVREKAR N, Butler K, Shapiro DE, Atuhaire P, et al
    Self-Reported Antiretroviral Adherence: Association with Maternal Viral Load Suppression in Postpartum Women Living with HIV-1 from Promoting Maternal and Infant Survival Everywhere (PROMISE), a Randomized Controlled Trial in Sub-Saharan Africa and In
    J Acquir Immune Defic Syndr. 2022 Sep 28. pii: 00126334-990000000-00117.
    >> Share

  49. CHAMMARTIN F, Darling K, Abela IA, Battegay M, et al
    CD4:CD8 ratio and CD8 cell count and their prognostic relevance for coronary heart disease events and stroke in antiretroviral treated individuals: The Swiss HIV Cohort Study.
    J Acquir Immune Defic Syndr. 2022 Sep 23. pii: 00126334-990000000-00116.
    >> Share

  50. PALELLA FJ, Hou Q, Li J, Mahnken J, et al
    Weight gain and metabolic effects in persons with HIV who switch to ART regimens containing integrase inhibitors or tenofovir alafenamide.
    J Acquir Immune Defic Syndr. 2022 Sep 23. pii: 00126334-990000000-00121.
    >> Share

  51. OPSTEEN S, Moylan D, Taiwo BO, Robertson KR, et al
    Intracellular cystatin B levels are altered in HIV-infected participants with respect to neurocognitive status and anti-retroviral therapy.
    J Acquir Immune Defic Syndr. 2022 Sep 9. pii: 00126334-990000000-00107.
    >> Share

  52. MORRIS SR, Jain S, Blumenthal J, Bolan R, et al
    Randomized Trial of Individualized Texting for Adherence Building (iTAB) plus Motivational Interviewing for PrEP Adherence in Transgender Individuals (The iM-PrEPT Study).
    J Acquir Immune Defic Syndr. 2022 Sep 8. pii: 00126334-990000000-00110.
    >> Share

  53. SOLANKE T, Kamau F, Esterhuizen T, Maartens G, et al
    Concentrations of Efavirenz, Tenofovir, and Emtricitabine in Obesity: A Cross-Sectional Study.
    J Acquir Immune Defic Syndr. 2022;91:101-108.
    >> Share

  54. MOLINA JM, Yazdanpanah Y, Afani Saud A, Bettacchi C, et al
    Brief Report: Efficacy and Safety of Oral Islatravir Once Daily in Combination With Doravirine Through 96 Weeks for Treatment-Naive Adults With HIV-1 Infection Receiving Initial Treatment With Islatravir, Doravirine, and Lamivudine.
    J Acquir Immune Defic Syndr. 2022;91:68-72.
    >> Share

  55. BEESHAM I, Mansoor LE, Joseph Davey DL, Palanee-Phillips T, et al
    Brief Report: Quantifiable Plasma Tenofovir Among South African Women Using Daily Oral Pre-exposure Prophylaxis During the ECHO Trial.
    J Acquir Immune Defic Syndr. 2022;91:26-30.
    >> Share

  56. COUTINHO CM, Warshaw MG, Duarte G, Stek A, et al
    Effects of initiating raltegravir-based versus efavirenz-based antiretroviral regimens during pregnancy on weight changes and perinatal outcomes: NICHD P1081.
    J Acquir Immune Defic Syndr. 2022 Sep 1. pii: 00126334-990000000-00100.
    >> Share

    August 2022
  57. CALZA L, Bon I, Pensalfine G, Vitale S, et al
    CHANGES IN SERUM INFLAMMATORY MARKERS IN ANTIRETROVIRAL THERAPY-NAIVE HIV-INFECTED PATIENTS STARTING DOLUTEGRAVIR/LAMIVUDINE OR TENOFOVIR ALAFENAMIDE/EMTRICITABINE/BICTEGRAVIR.
    J Acquir Immune Defic Syndr. 2022 Aug 18. pii: 00126334-990000000-00095.
    >> Share

  58. DRAGONI F, Rossetti B, Lombardi F, Raffaelli CS, et al
    Dynamics of total and intact HIV-1 DNA in virologically suppressed patients switching to DTG- or ATV-based dual therapy.
    J Acquir Immune Defic Syndr. 2022 Aug 15. pii: 00126334-990000000-00092.
    >> Share

  59. NEMATADZIRA TG, Murnane PM, Odiase OJ, Bacchetti P, et al
    ANTIRETROVIRAL THERAPY ADHERENCE DURING AND POST BREASTFEEDING CESSATION MEASURED BY TENOFOVIR LEVELS IN HAIR.
    J Acquir Immune Defic Syndr. 2022 Aug 11. pii: 00126334-990000000-00086.
    >> Share

  60. WEISS F, von Both U, Rack-Hoch A, Sollinger F, et al
    HIV-Positive and Breastfeeding in High-Income Settings: 5-year Experience from a Perinatal Center in Germany.
    J Acquir Immune Defic Syndr. 2022 Aug 9. pii: 00126334-990000000-00088.
    >> Share

  61. ESBER A, Dear N, Shah N, Kibuuka H, et al
    Virologic impact of the dolutegravir transition: prospective results from the multinational African Cohort Study.
    J Acquir Immune Defic Syndr. 2022 Aug 3. pii: 00126334-990000000-00084.
    >> Share

    May 2022
  62. KIWEEWA FM, Tierney C, Butler K, Peters MG, et al
    Impact of Antiretroviral Regimen on Pregnancy and Infant Outcomes in Women with HIV/ HBV Co-infection.
    J Acquir Immune Defic Syndr. 2022 May 27. pii: 00126334-990000000-00050.
    >> Share

  63. KHERABI Y, de Castro N, Sellier PO, Hamet G, et al
    Efficacy and safety of efavirenz, raltegravir and dolutegravir in HIV-1/TB co-infection. A multicenter retrospective cohort study in France.
    J Acquir Immune Defic Syndr. 2022 May 26. pii: 00126334-990000000-00052.
    >> Share

    April 2022
  64. CANNON CA, Ramchandani MS, Buskin S, Dombrowski J, et al
    Previous Pre-Exposure Prophylaxis Use Among Men Who Have Sex with Men Newly Diagnosed with HIV Infection in King County, Washington.
    J Acquir Immune Defic Syndr. 2022 Apr 29. pii: 00126334-990000000-00035.
    >> Share

  65. SCHROTER J, Anelone AJN, de Boer RJ
    Quantification of CD4 Recovery in Early-Treated Infants Living With HIV.
    J Acquir Immune Defic Syndr. 2022;89:546-557.
    >> Share

  66. MORRIS S, Cottrell M, Rawlings SA, Peterson S, et al
    Genital Inflammation Is Not Associated With Decreased Vaginal Tenofovir Concentrations in Women Taking Oral PrEP.
    J Acquir Immune Defic Syndr. 2022;89:390-395.
    >> Share

    March 2022
  67. PATHELA P, Qasmieh S, Gandhi M, Rozen E, et al
    Use of remnant specimens to assess use of HIV pre-exposure prophylaxis (PrEP) among populations with risk for HIV infection: A novel approach.
    J Acquir Immune Defic Syndr. 2022 Mar 31. pii: 00126334-990000000-00015.
    >> Share

  68. MENG W, Chen M, Song Y, Zhang H, et al
    Prevalence and Risk Factors of Low Bone Mineral Density in HIV/AIDS Patients: a Chinese Cross-sectional Study.
    J Acquir Immune Defic Syndr. 2022 Mar 22. pii: 00126334-990000000-00011.
    >> Share

  69. HABERER JE, Mugo N, Bukusi EA, Ngure K, et al
    Understanding Pre-Exposure Prophylaxis Adherence in Young Women in Kenya.
    J Acquir Immune Defic Syndr. 2022;89:251-260.
    >> Share

    February 2022
  70. BROOKS KM, Pinilla M, Stek AM, Shapiro DE, et al
    Pharmacokinetics of tenofovir alafenamide with boosted protease inhibitors in pregnant and postpartum women living with HIV: Results from IMPAACT P1026s.
    J Acquir Immune Defic Syndr. 2022 Feb 21. pii: 00126334-900000000-95687.
    >> Share

  71. ZHAO Y, Hohlfeld A, Namale P, Meintjes G, et al
    Risk of immune reconstitution inflammatory syndrome with integrase inhibitors versus other classes of antiretrovirals: a systematic review and meta-analysis of randomised trials.
    J Acquir Immune Defic Syndr. 2022 Feb 14. pii: 00126334-900000000-95690.
    >> Share

  72. MONTANO M, Landay A, Perkins M, Holstad M, et al
    HIV and Aging in the Era of ART and COVID-19: Symposium Overview.
    J Acquir Immune Defic Syndr. 2022;89.
    >> Share

  73. PALLIKKUTH S, Pahwa S
    HIV and Aging in the Era of ART and COVID-19.
    J Acquir Immune Defic Syndr. 2022;89.
    >> Share

    January 2022
  74. SUAREZ-GARCIA I, Ruiz-Alguero M, Alejos B, Garcia-Yubero C, et al
    Patients' experiences and opinions after de-simplification of their single-tablet regimens for the treatment of HIV infection: a survey in a multicentre cohort.
    J Acquir Immune Defic Syndr. 2022 Jan 26. pii: 00126334-900000000-95704.
    >> Share

  75. CHEN JS, Pettifor AE, Nelson JA, Phiri S, et al
    Blood and genital fluid viral load trajectories among treated and untreated persons with acute HIV infection in Malawi.
    J Acquir Immune Defic Syndr. 2022 Jan 17. pii: 00126334-900000000-95712.
    >> Share

  76. STARBUCK L, Golub SA, Klein A, Harris AB, et al
    Transgender Women and PrEP Care: High PrEP Adherence in a Real-World Health Care Setting in New York City.
    J Acquir Immune Defic Syndr. 2022 Jan 10. pii: 00126334-900000000-95713.
    >> Share

  77. MAYER KH, Gelman M, Holmes J, Kraft J, et al
    Safety and Tolerability of Once Daily Co-Formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide for Post-Exposure Prophylaxis after Sexual Exposure.
    J Acquir Immune Defic Syndr. 2022 Jan 4. pii: 00126334-900000000-95720.
    >> Share

  78. OUATTARA LA, Thurman AR, Jacot TA, Cottrell M, et al
    Genital Mucosal Drug Concentrations and anti-HIV Activity in Tenofovir-Based PrEP Products: Intravaginal Ring vs. Oral Administration.
    J Acquir Immune Defic Syndr. 2022;89:87-97.
    >> Share

    December 2021
  79. DIJKSTRA S, Hofstra LM, Mudrikova T, Wensing AMJ, et al
    Lower incidence of HIV-1 blips observed during integrase inhibitor-based combination antiretroviral therapy.
    J Acquir Immune Defic Syndr. 2021 Dec 24. pii: 00126334-900000000-95731.
    >> Share

  80. MUJUGIRA A, Nakyanzi A, Nabaggala MS, Muwonge TR, et al
    Effect of HIV Self-Testing on PrEP Adherence among Gender Diverse Sex Workers in Uganda: A Randomized Trial.
    J Acquir Immune Defic Syndr. 2021 Dec 23. pii: 00126334-900000000-95734.
    >> Share

  81. RIAL-CRESTELO D, Bisbal O, Font R, De Lagarde M, et al
    Incidence and severity of SARS-CoV-2 infection in HIV-infected individuals during the first year of the pandemic.
    J Acquir Immune Defic Syndr. 2021 Dec 23. pii: 00126334-900000000-95733.
    >> Share

  82. SEVELIUS JM, Glidden DV, Deutsch M, Welborn L, et al
    Uptake, Retention, and Adherence to Pre-exposure Prophylaxis (PrEP) in TRIUMPH: A Peer-Led PrEP Demonstration Project for Transgender Communities in Oakland and Sacramento, California.
    J Acquir Immune Defic Syndr. 2021;88.
    >> Share

  83. LORENZ DR, Mukerji SS, Misra V, Uno H, et al
    Predictors of Transition to Frailty in Middle-Aged and Older People With HIV: A Prospective Cohort Study.
    J Acquir Immune Defic Syndr. 2021;88:518-527.
    >> Share

  84. LOPES J, Grimwood A, Ngorima-Mabhena N, Tiam A, et al
    Out-of-Facility Multimonth Dispensing of Antiretroviral Treatment: A Pooled Analysis Using Individual Patient Data From Cluster-Randomized Trials in Southern Africa.
    J Acquir Immune Defic Syndr. 2021;88:477-486.
    >> Share

  85. D'ANTONI ML, Andreatta K, Acosta R, Martin H, et al
    Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Efficacy in Participants with Pre-existing Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials.
    J Acquir Immune Defic Syndr. 2021 Dec 10. pii: 00126334-900000000-95741.
    >> Share

  86. ABUOGI LL, Castillo-Mancilla J, Hampanda K, Owuor K, et al
    Tenofovir Diphosphate in Dried Blood Spots in pregnant and postpartum women with HIV in Kenya: a novel approach to measuring peripartum adherence.
    J Acquir Immune Defic Syndr. 2021 Dec 9. pii: 00126334-900000000-95743.
    >> Share

  87. BIEN-GUND CH, Bilker W, Schnoll RA, Tyndale RF, et al
    Nicotine metabolism ratio increases in HIV-positive smokers on effective antiretroviral therapy: a cohort study.
    J Acquir Immune Defic Syndr. 2021 Dec 7. pii: 00126334-900000000-95751.
    >> Share

  88. BEKKER A, Rabie H, Salvadori N, du Toit S, et al
    Pharmacokinetics and safety of the abacavir/lamivudine/lopinavir/ritonavir fixed-dose granule formulation (4-in-1) in neonates: PETITE study.
    J Acquir Immune Defic Syndr. 2021 Dec 2. pii: 00126334-900000000-95754.
    >> Share

  89. REES H, Chersich MF, Munthali RJ, Brumskine W, et al
    HIV Incidence Among Pregnant and Nonpregnant Women in the FACTS-001 Trial: Implications for HIV Prevention, Especially PrEP Use.
    J Acquir Immune Defic Syndr. 2021;88:376-383.
    >> Share

    November 2021
  90. CHAI PR, Mohamed Y, Bustamante MJ, Goodman GR, et al
    DigiPrEP: A pilot trial to evaluate the feasibility, acceptability, and accuracy of a digital pill system to measure PrEP adherence in men who have sex with men who use substances.
    J Acquir Immune Defic Syndr. 2021 Nov 8. pii: 00126334-900000000-95762.
    >> Share

  91. CALZA L, Legnani G, Fulgaro C, Verucchi G, et al
    CHANGES IN SERUM INFLAMMATORY MARKERS IN ANTIRETROVIRAL THERAPY-NAIVE HIV-INFECTED PATIENTS STARTING DOLUTEGRAVIR/LAMIVUDINE OR DOLUTEGRAVIR/LAMIVUDINE/ABACAVIR.
    J Acquir Immune Defic Syndr. 2021 Nov 5. pii: 00126334-900000000-95763.
    >> Share

  92. MOMPER JD, Wang J, Stek A, Shapiro DE, et al
    Pharmacokinetics of atazanavir boosted with cobicistat in pregnant and postpartum women with HIV.
    J Acquir Immune Defic Syndr. 2021 Nov 2. pii: 00126334-900000000-95765.
    >> Share

    October 2021
  93. NYANDIKO W, Holland S, Vreeman R, DeLong AK, et al
    HIV-1 Treatment Failure, Drug Resistance and Clinical Outcomes in Perinatally-Infected Children and Adolescents Failing 1st-Line Antiretroviral Therapy in Western Kenya.
    J Acquir Immune Defic Syndr. 2021 Oct 28. pii: 00126334-900000000-95768.
    >> Share

  94. SHAFFER D, Kumwenda J, Chen H, Akelo V, et al
    Brief Report: No Differences Between Lopinavir/ritonavir and non-Nucleoside Reverse Transcriptase Inhibitor-based Antiretroviral Therapy on Clearance of Plasmodium falciparum Subclinical Parasitemia in Adults Living With HIV Starting Treatment (A5297)
    J Acquir Immune Defic Syndr. 2021 Oct 19. pii: 00126334-900000000-95780.
    >> Share

  95. SAHAGUN SJ, Yeramosu T, Purdy JB, Reynolds JC, et al
    Associations between Central Obesity and Life-Long Antiviral Therapy in Adults Living with HIV Acquired from Early Childhood.
    J Acquir Immune Defic Syndr. 2021 Oct 19. pii: 00126334-900000000-95778.
    >> Share

  96. CAMPBELL L, Barbini B, Burling K, Cromarty B, et al
    Safety of Tenofovir Alafenamide in People With HIV Who Experienced Proximal Renal Tubulopathy on Tenofovir Disoproxil Fumarate.
    J Acquir Immune Defic Syndr. 2021;88:214-219.
    >> Share

  97. WOMACK JA, Murphy TE, Ramsey C, Bathulapalli H, et al
    Brief Report: Are Serious Falls Associated With Subsequent Fragility Fractures Among Veterans Living With HIV?
    J Acquir Immune Defic Syndr. 2021;88:192-196.
    >> Share

    September 2021
  98. HOGH J, Gelpi M, Skovsgaard MH, Afzal S, et al
    HIV infection is associated with type 2 diabetes mellitus.
    J Acquir Immune Defic Syndr. 2021 Sep 14. pii: 00126334-900000000-95806.
    >> Share

  99. HAGINS D, Kumar P, Saag M, Wurapa AK, et al
    Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study.
    J Acquir Immune Defic Syndr. 2021;88:86-95.
    >> Share

  100. MOLDT B, Parvangada A, Martin R, Pace C, et al
    Evaluation of Broadly Neutralizing Antibody Sensitivity by Genotyping and Phenotyping for Qualifying Participants to HIV Clinical Trials.
    J Acquir Immune Defic Syndr. 2021;88:61-69.
    >> Share

    August 2021
  101. CICCULLO A, Borghi V, Giacomelli A, Cossu MV, et al
    Five years with dolutegravir plus lamivudine as a switch strategy: much more than a positive finding.
    J Acquir Immune Defic Syndr. 2021 Aug 20. pii: 00126334-900000000-95820.
    >> Share

  102. ORKIN C, Ajana F, Kityo C, Koenig E, et al
    Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 Trials.
    J Acquir Immune Defic Syndr. 2021 Aug 20. pii: 00126334-900000000-95811.
    >> Share

  103. DAT VQ, Lyss S, Hoai Dung NT, Hung LM, et al
    Prevalence of advanced HIV disease, cryptococcal antigenemia and suboptimal clinical outcomes among those enrolled in care in Vietnam.
    J Acquir Immune Defic Syndr. 2021 Aug 20. pii: 00126334-900000000-95822.
    >> Share

  104. FRENKEL LM, Leavitt Morrison R, Fuller TL, Isabel Gouvea M, et al
    Vaginal Viral Shedding with Undetectable Plasma HIV Viral Load in Pregnant Women Receiving Two Different Antiretroviral Regimens: A Randomized Clinical Trial.
    J Acquir Immune Defic Syndr. 2021 Aug 7. pii: 00126334-900000000-95826.
    >> Share

  105. LE GUILLOU A, Buchbinder S, Scott H, Liu A, et al
    Population Impact and Efficiency of Improvements to HIV PrEP Under Conditions of High ART Coverage among San Francisco Men Who Have Sex with Men.
    J Acquir Immune Defic Syndr. 2021 Aug 5. pii: 00126334-900000000-95830.
    >> Share

  106. HERMANS LE, Nijhuis M, Tempelman HA, Houts T, et al
    Point-of-Care Detection of Nonadherence to Antiretroviral Treatment for HIV-1 in Resource-Limited Settings Using Drug Level Testing for Efavirenz, Lopinavir, and Dolutegravir: A Validation and Pharmacokinetic Simulation Study.
    J Acquir Immune Defic Syndr. 2021;87:1072-1078.
    >> Share

    July 2021
  107. CHAISSON LH, Saraceni V, Cohn S, Cavalcante SC, et al
    Yield of repeat tuberculin skin testing for people living with HIV in Brazil.
    J Acquir Immune Defic Syndr. 2021 Jul 30. pii: 00126334-900000000-95833.
    >> Share

  108. KOUSARI A, Moser C, Olefsky M, Brown TT, et al
    Poorer Muscle Quality and Quantity with ART Initiation is Associated with Greater Inflammation and Immune Activation.
    J Acquir Immune Defic Syndr. 2021 Jul 28. pii: 00126334-900000000-95835.
    >> Share

  109. SALAMA E, Hill L, Patel N, Best BM, et al
    Pharmacokinetics of bictegravir and tenofovir in combination with darunavir/cobicistat in treatment-experienced persons with HIV.
    J Acquir Immune Defic Syndr. 2021 Jul 19. pii: 00126334-900000000-95840.
    >> Share

  110. CELERINO DA SILVA R, Pereira Alves NM, Gondim Silva ML, Agrelli A, et al
    Polymorphisms in TNF-alpha/TNFR1 pathway genes are associated with CD4+ T cells recovery in HIV-1-infected individuals on antiretroviral therapy.
    J Acquir Immune Defic Syndr. 2021 Jul 14. pii: 00126334-900000000-95845.
    >> Share

  111. LELLOUCHE L, Gutierrez LA, Leclercq P, Zaegel-Faucher O, et al
    Frailty in Aging People Living With HIV: a matched controlled Study.
    J Acquir Immune Defic Syndr. 2021 Jul 6. pii: 00126334-900000000-95850.
    >> Share

    June 2021
  112. GIACOMELLI A, Cozzi-Lepri A, Cingolani A, Tavelli A, et al
    Does syphilis increase the risk of HIV-RNA elevation >200 copies/mL in HIV positive patients under effective antiretroviral treatment? Data from the ICONA cohort.
    J Acquir Immune Defic Syndr. 2021 Jun 15. pii: 00126334-900000000-95862.
    >> Share

  113. SILHOL R, Coupland H, Baggaley RF, Miller L, et al
    What is the burden of heterosexually-acquired HIV due to HSV-2? Global and regional model-based estimates of the proportion and number of HIV infections attributable to HSV-2 infection.
    J Acquir Immune Defic Syndr. 2021 Jun 9. pii: 00126334-900000000-95864.
    >> Share

  114. FLYNN PM, Taha TE, Cababasay M, Butler K, et al
    Association of Maternal Viral Load and CD4 Count with Perinatal HIV-1 Transmission Risk during Breastfeeding in the PROMISE Postpartum Component.
    J Acquir Immune Defic Syndr. 2021 Jun 8. pii: 00126334-900000000-95865.
    >> Share

  115. CHAWANA TD, Nhachi CFB, Nathoo K, Ngara B, et al
    Ritonavir concentrations in hair predict virologic outcomes in HIV-infected adolescents with virologic failure on atazanavir/ritonavir-based second-line treatment.
    J Acquir Immune Defic Syndr. 2021 Jun 8. pii: 00126334-900000000-95863.
    >> Share

    May 2021
  116. GUZMAN VA, Cham H, Gutierrez J, Byrd D, et al
    The Longitudinal Effects of Blood Pressure and Hypertension on Neurocognitive Performance in People Living with HIV.
    J Acquir Immune Defic Syndr. 2021 May 31. pii: 00126334-900000000-95866.
    >> Share

  117. JASANTHA O, Kabanda S, Malaba TR, Lesosky M, et al
    Viral load monitoring in pregnancy to predict peripartum viraemia in South Africa.
    J Acquir Immune Defic Syndr. 2021 May 28. pii: 00126334-900000000-95870.
    >> Share

  118. JOHNSON KA, Okochi H, Glidden DV, Gandhi M, et al
    Brief Report: No Difference in Urine Tenofovir Levels in Patients Living with HIV on Unboosted vs Dose-Adjusted Boosted Tenofovir Alafenamide.
    J Acquir Immune Defic Syndr. 2021 May 12. pii: 00126334-900000000-95879.
    >> Share

  119. DIAS JP, Haberlen SA, Dobs AS, Lake JE, et al
    Longitudinal changes in sex hormone-binding globulin in men with HIV.
    J Acquir Immune Defic Syndr. 2021 May 10. pii: 00126334-900000000-95884.
    >> Share

  120. JIAMSAKUL A, Boyd M, Choi JY, Edmiston N, et al
    Trends in follow-up visits among people living with HIV - results from the TREAT Asia and Australian HIV Observational Databases (TAHOD and AHOD).
    J Acquir Immune Defic Syndr. 2021 May 10. pii: 00126334-900000000-95883.
    >> Share

    April 2021
  121. BOSSARD C, Schramm B, Wanjala S, Jain L, et al
    High prevalence of NRTI and NNRTI drug resistance among ART-experienced, hospitalized inpatients.
    J Acquir Immune Defic Syndr. 2021 Apr 1. pii: 00126334-900000000-95902.
    >> Share

    February 2021
  122. KUMAR P, Johnson M, Molina JM, Rizzardini G, et al
    Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through Week 144 in the DRIVE-SHIFT Trial.
    J Acquir Immune Defic Syndr. 2021 Feb 17. pii: 00126334-900000000-95929.
    >> Share

  123. CINDI Z, Maartens G, Bradford Y, Venter F, et al
    Genetic Associations with Weight Gain among South Africans who Initiated Dolutegravir- and Tenofovir-containing Regimens.
    J Acquir Immune Defic Syndr. 2021 Feb 17. pii: 00126334-900000000-95930.
    >> Share

  124. VAN WYK J, Ait-Khaled M, Santos J, Scholten S, et al
    Improvement in Metabolic Health Parameters at Week 48 After Switching From a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen to the 2-Drug Regimen of Dolutegravir/Lamivudine: The TANGO Study.
    J Acquir Immune Defic Syndr. 2021 Feb 12. pii: 00126334-900000000-95934.
    >> Share

  125. KOHN JN, Loop MS, Kim-Chang JJ, Garvie PA, et al
    Trajectories of depressive symptoms, neurocognitive function and viral suppression with antiretroviral therapy among youth with HIV over 36 months.
    J Acquir Immune Defic Syndr. 2021 Feb 12. pii: 00126334-900000000-95933.
    >> Share

  126. HUANG SH, Huang WC, Lin SW, Chuang YC, et al
    Impact of efavirenz mid-dose plasma concentration on long-term weight change among virologically suppressed people living with HIV.
    J Acquir Immune Defic Syndr. 2021 Feb 11. pii: 00126334-900000000-95941.
    >> Share

  127. MGODI NM, Takuva S, Edupuganti S, Karuna S, et al
    A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection in women in sub-Saharan Africa: baseline findings.
    J Acquir Immune Defic Syndr. 2021 Feb 11. pii: 00126334-900000000-95944.
    >> Share

  128. PRICE JT, Vwalika B, Edwards JK, Cole SR, et al
    Maternal HIV infection and spontaneous versus provider-initiated preterm birth in an urban Zambian cohort.
    J Acquir Immune Defic Syndr. 2021 Feb 11. pii: 00126334-900000000-95942.
    >> Share

  129. PELCHEN-MATTHEWS A, Borges AH, Reekie J, Rasmussen LD, et al
    Prevalence and Outcomes for Heavily Treatment-Experienced (HTE) Individuals Living with Human Immunodeficiency Virus in a European Cohort.
    J Acquir Immune Defic Syndr. 2021 Feb 11. pii: 00126334-900000000-95940.
    >> Share

    January 2021
  130. WAIRIMU F, Ward NC, Liu Y, Dwivedi G, et al
    Cardiac transplantation in HIV positive patients: a narrative review.
    J Acquir Immune Defic Syndr. 2021 Jan 29. pii: 00126334-900000000-95951.
    >> Share

  131. JOHNSON KA, Chen MJ, Kohn R, Sachdev D, et al
    Acute HIV at the time of initiation of Pre or Post Exposure Prophylaxis: Impact on drug-resistance and clinical outcomes.
    J Acquir Immune Defic Syndr. 2021 Jan 28. pii: 00126334-900000000-95954.
    >> Share

  132. VAN DER HEIJDEN WA, Wan J, Van de Wijer L, Jaeger M, et al
    Plasmatic coagulation capacity correlates with inflammation and abacavir-use during chronic HIV-infection.
    J Acquir Immune Defic Syndr. 2021 Jan 26. pii: 00126334-900000000-95956.
    >> Share

  133. DUNN D, Price H, Vudriko T, Kityo C, et al
    New Insights on Long-Term Hepatitis B Virus Responses in HIV-Hepatitis B virus Co-infected Patients: Implications for Antiretroviral Management in Hepatitis B virus-Endemic Settings.
    J Acquir Immune Defic Syndr. 2021;86:98-103.
    >> Share

  134. ELLSWORTH GB, Burke LA, Wells MT, Mishra S, et al
    Randomized Pilot Study of an Advanced Smart-Pill Bottle as an Adherence Intervention in Patients With HIV on Antiretroviral Treatment.
    J Acquir Immune Defic Syndr. 2021;86:73-80.
    >> Share

    December 2020
  135. O'HALLORAN JA, Wang K, Spence AB, Williams DW, et al
    Integrase Strand Transfer Inhibitor Start or Switch Impacts Learning in Women with HIV.
    J Acquir Immune Defic Syndr. 2020;Publish Ahead of Print.
    >> Share

  136. GINGRICH D, Deitchman AN, Kantor A, Huang L, et al
    Methotrexate Decreases Tenofovir Exposure in Antiretroviral-Suppressed Individuals Living With HIV.
    J Acquir Immune Defic Syndr. 2020;85:651-658.
    >> Share

  137. PEREZ-VALERO I, Llibre JM, Castagna A, Pulido F, et al
    Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Adults With HIV and M184V/I Mutation.
    J Acquir Immune Defic Syndr. 2020 Dec 10. doi: 10.1097/QAI.0000000000002595.
    >> Share

  138. LEFEBVRE M, Walencik A, Allavena C, Billaud E, et al
    Rate of DRESS Syndrome With Raltegravir and Role of the HLA-B*53: 01 Allele.
    J Acquir Immune Defic Syndr. 2020;85:e77-e80.
    >> Share

  139. MANN SC, Morrow M, Coyle RP, Coleman SS, et al
    Lower Cumulative Antiretroviral Exposure in People Living With HIV and Diabetes Mellitus.
    J Acquir Immune Defic Syndr. 2020;85:483-488.
    >> Share

  140. BK K, Tiwari S, Chhapola V, Debnath E, et al
    Brief Report: Subclinical Kidney Dysfunction in HIV-Infected Children: A Cross-Sectional Study.
    J Acquir Immune Defic Syndr. 2020;85:470-474.
    >> Share

  141. HEBEL S, Kahn-Woods E, Malone-Thomas S, McNeese M, et al
    Brief Report: Discrepancies Between Self-Reported Adherence and a Biomarker of Adherence in Real-World Settings.
    J Acquir Immune Defic Syndr. 2020;85:454-457.
    >> Share

  142. MOORE JR, Donnell DJ, Boily MC, Mitchell KM, et al
    Model-Based Predictions of HIV Incidence Among African Women Using HIV Risk Behaviors and Community-Level Data on Male HIV Prevalence and Viral Suppression.
    J Acquir Immune Defic Syndr. 2020;85:423-429.
    >> Share

    November 2020
  143. HUANG YS, Cheng CY, Liou BH, Lu PL, et al
    Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide as maintenance treatment in HIV/HBV-coinfected patients.
    J Acquir Immune Defic Syndr. 2020 Nov 30. doi: 10.1097/QAI.0000000000002589.
    >> Share

  144. CELERINO DA SILVA R, Segat L, Kuhn L, Bogo Chies JA, et al
    Association of single nucleotide polymorphisms in HLA-C and ZNRD1 genes with HIV-1 mother to child transmission in Zambia population.
    J Acquir Immune Defic Syndr. 2020 Nov 23. doi: 10.1097/QAI.0000000000002584.
    >> Share

  145. MULATO A, Acosta R, Chang S, Martin R, et al
    Simulating HIV Breakthrough and Resistance Development During Variable Adherence to Antiretroviral Treatment.
    J Acquir Immune Defic Syndr. 2020 Nov 9. doi: 10.1097/QAI.0000000000002562.
    >> Share

    October 2020
  146. ROTH AM, Tran NK, Felsher MA, Gadegbeku AB, et al
    Integrating HIV pre-exposure prophylaxis with community-based syringe services for women who inject drugs: Results from the Project SHE demonstration study.
    J Acquir Immune Defic Syndr. 2020 Oct 28. doi: 10.1097/QAI.0000000000002558.
    >> Share

  147. RUDERMAN SA, Crane HM, Nance RM, Whitney BM, et al
    Weight gain following antiretroviral therapy (ART) initiation in ART-naive people living with HIV in the current treatment era.
    J Acquir Immune Defic Syndr. 2020 Oct 28. doi: 10.1097/QAI.0000000000002556.
    >> Share

  148. AMELE S, Peters L, Rodger A, Lundgren J, et al
    Effectiveness and safety of IFN-free DAA HCV therapy in HIV/HCV co-infected persons: Results from a pan-European study.
    J Acquir Immune Defic Syndr. 2020 Oct 15. doi: 10.1097/QAI.0000000000002541.
    >> Share

  149. KAPITO-TEMBO AP, Bauleni A, Wesevich A, Ongubo D, et al
    Growth and neurodevelopment outcomes in HIV, tenofovir and efavirenz exposed breastfed infants in PMTCT Option B+ program in Malawi.
    J Acquir Immune Defic Syndr. 2020 Oct 5. doi: 10.1097/QAI.0000000000002515.
    >> Share

  150. SURIAL B, Beguelin C, Chave JP, Stockle M, et al
    Brief Report: Switching From TDF to TAF in HIV/HBV-Coinfected Individuals With Renal Dysfunction-A Prospective Cohort Study.
    J Acquir Immune Defic Syndr. 2020;85:227-232.
    >> Share

    September 2020
  151. CLARKE DF, Lommerse J, Acosta EP, Cababasay MP, et al
    IMPACT OF LOW BIRTH WEIGHT AND PREMATURITY ON NEONATAL RALTEGRAVIR PHARMACOKINETICS: IMPAACT P1097.
    J Acquir Immune Defic Syndr. 2020 Sep 9. doi: 10.1097/QAI.0000000000002492.
    >> Share

  152. MARTIN EA, Lai MT, Ngo W, Feng M, et al
    Review of Doravirine Resistance Patterns Identified in Participants During Clinical Development.
    J Acquir Immune Defic Syndr. 2020 Sep 9. doi: 10.1097/QAI.0000000000002496.
    >> Share

  153. YANUAR SAFRI A, Gaff J, Octaviana F, Dewanto Setiawan D, et al
    Demographic and genetic associations with markers of small and large fibre sensory neuropathy in HIV patients treated without stavudine.
    J Acquir Immune Defic Syndr. 2020 Sep 7. doi: 10.1097/QAI.0000000000002503.
    >> Share

    August 2020
  154. MOORE JR, Donnell DJ, Boily MC, Mitchell KM, et al
    Model-based predictions of HIV incidence among African women using HIV risk behaviors and community-level data on male HIV prevalence and viral suppression.
    J Acquir Immune Defic Syndr. 2020 Aug 24. doi: 10.1097/QAI.0000000000002481.
    >> Share

  155. HEBEL S, Kahn-Woods E, Malone-Thomas S, McNeese M, et al
    Discrepancies between self-reported adherence and a biomarker of adherence in real-world settings.
    J Acquir Immune Defic Syndr. 2020 Aug 20. doi: 10.1097/QAI.0000000000002486.
    >> Share

  156. LEFEBVRE M, Walencik A, Allavena C, Billaud E, et al
    Rate of drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome with raltegravir and role of the HLA-B*53: 01 allele.
    J Acquir Immune Defic Syndr. 2020 Aug 17. doi: 10.1097/QAI.0000000000002474.
    >> Share

  157. VECCHIO A, Robertson K, Saylor D, Nakigozi G, et al
    Neurocognitive Effects of Antiretroviral Initiation Among People Living With HIV in Rural Uganda.
    J Acquir Immune Defic Syndr. 2020;84:534-542.
    >> Share

  158. AUDSLEY J, Avihingsanon A, Littlejohn M, Bowden S, et al
    Long-Term TDF-Inclusive ART and Progressive Rates of HBsAg Loss in HIV-HBV Coinfection-Lessons for Functional HBV Cure?
    J Acquir Immune Defic Syndr. 2020;84:527-533.
    >> Share

  159. EGAN JE, Ho K, Stall R, Drucker MT, et al
    Feasibility of Short-Term PrEP Uptake for Men Who Have Sex With Men With Episodic Periods of Increased HIV Risk.
    J Acquir Immune Defic Syndr. 2020;84:508-513.
    >> Share

  160. BK K, Tiwari S, Chhapola V, Debnath E, et al
    Subclinical kidney dysfunction in HIV infected children: a cross-sectional study.
    J Acquir Immune Defic Syndr. 2020 Aug 5. doi: 10.1097/QAI.0000000000002470.
    >> Share

    July 2020
  161. GAO G, Wang A, Wang S, Qian F, et al
    A retrospective evaluation on the efficacy of Lopinavir/ritonavir and chloroquine to treat non-severe COVID-19 patients.
    J Acquir Immune Defic Syndr. 2020 Jul 22. doi: 10.1097/QAI.0000000000002452.
    >> Share

  162. MANN SC, Morrow M, Coyle RP, Coleman SS, et al
    Lower Cumulative Antiretroviral Exposure in People Living with Hiv and Diabetes Mellitus.
    J Acquir Immune Defic Syndr. 2020 Jul 22. doi: 10.1097/QAI.0000000000002460.
    >> Share

  163. ACOSTA RK, Willkom M, Andreatta K, Liu H, et al
    Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) from Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-Existing NRTI Resistance.
    J Acquir Immune Defic Syndr. 2020 Jul 21. doi: 10.1097/QAI.0000000000002454.
    >> Share

  164. VAN WYK J, Orkin C, Rubio R, Bogner J, et al
    Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and -2 Randomized Clinical Trials.
    J Acquir Immune Defic Syndr. 2020 Jul 13. doi: 10.1097/QAI.0000000000002449.
    >> Share

  165. SURIAL B, Beguelin C, Chave JP, Stockle M, et al
    Switching from TDF to TAF in HIV/HBV co-infected individuals with renal dysfunction - a prospective cohort study.
    J Acquir Immune Defic Syndr. 2020 Jul 2. doi: 10.1097/QAI.0000000000002429.
    >> Share


  166. Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials: Erratum.
    J Acquir Immune Defic Syndr. 2020;84:e21.
    >> Share

  167. YAGER J, Castillo-Mancilla J, Ibrahim ME, Brooks KM, et al
    Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS Study.
    J Acquir Immune Defic Syndr. 2020;84:323-330.
    >> Share

    June 2020
  168. TARLETON J, Chen BA, Meyn LA, Hendrix CW, et al
    Pharmacokinetic and pharmacodynamic impacts of depot medroxyprogesterone acetate use on HIV pre-exposure prophylaxis in women.
    J Acquir Immune Defic Syndr. 2020 Jun 18. doi: 10.1097/QAI.0000000000002421.
    >> Share

    May 2020
  169. EL KAMARI V, Hileman CO, Kosco J, Mccomsey GA, et al
    Sleeve Gastrectomy compared to Roux-en-Y Gastric Bypass in individuals living with HIV.
    J Acquir Immune Defic Syndr. 2020 May 15. doi: 10.1097/QAI.0000000000002392.
    >> Share

    April 2020
  170. LEE SA, Telwatte S, Hatano H, Kashuba ADM, et al
    Antiretroviral Therapy Concentrations Differ in Gut vs. Lymph Node Tissues and Are Associated With HIV Viral Transcription by a Novel RT-ddPCR Assay.
    J Acquir Immune Defic Syndr. 2020;83:530-537.
    >> Share

  171. LAVERGNE S, Umlauf A, McCutchan A, Heaton R, et al
    Impact of Latent Tuberculosis Infection on Neurocognitive Functioning and Inflammation in HIV-Infected and Uninfected South Indians.
    J Acquir Immune Defic Syndr. 2020 Apr 9. doi: 10.1097/QAI.0000000000002368.
    >> Share

  172. NYIRENDA M, Ngongondo M, Kang M, Umbleja T, et al
    Early progression and immune reconstitution inflammatory syndrome during treatment of mild-to-moderate Kaposi sarcoma in sub-Saharan Africa and South America: Incidence, long-term outcomes and effects of early chemotherapy.
    J Acquir Immune Defic Syndr. 2020 Apr 4. doi: 10.1097/QAI.0000000000002361.
    >> Share

    March 2020
  173. O'HALLORAN JA, Sahrmann J, Butler AM, Olsen MA, et al
    Integrase Strand Transfer Inhibitors are associated with lower risk of incident Cardiovascular Disease in People Living with HIV.
    J Acquir Immune Defic Syndr. 2020 Mar 25. doi: 10.1097/QAI.0000000000002357.
    >> Share

  174. LALLEMANT M, Amzal B, Sripan P, Urien S, et al
    Perinatal antiretroviral intensification to prevent intrapartum HIV transmission when antenatal antiretroviral therapy is initiated less than 8 weeks prior to delivery.
    J Acquir Immune Defic Syndr. 2020 Mar 19. doi: 10.1097/QAI.0000000000002350.
    >> Share

  175. DAVEY S, Ajibola G, Maswabi K, Sakoi M, et al
    Mother-to-Child HIV Transmission with in utero Dolutegravir vs. Efavirenz in Botswana.
    J Acquir Immune Defic Syndr. 2020 Mar 16. doi: 10.1097/QAI.0000000000002338.
    >> Share

  176. SPINELLI MA, Rodrigues WC, Wang G, Vincent M, et al
    HIGH ACCURACY OF A REAL-TIME URINE ANTIBODY-BASED TENOFOVIR POINT-OF-CARE TEST COMPARED TO LABORATORY-BASED ELISA IN DIVERSE POPULATIONS.
    J Acquir Immune Defic Syndr. 2020 Mar 10. doi: 10.1097/QAI.0000000000002322.
    >> Share

  177. SILHOL R, Boily MC, Dimitrov D, German D, et al
    Understanding the HIV epidemic among MSM in Baltimore: a modelling study estimating the impact of past HIV interventions and who acquired and contributed to infections.
    J Acquir Immune Defic Syndr. 2020 Mar 3. doi: 10.1097/QAI.0000000000002340.
    >> Share

  178. SHIAU S, Yin MT, Strehlau R, Burke M, et al
    Deficits in bone architecture and strength in children living with HIV on antiretroviral therapy.
    J Acquir Immune Defic Syndr. 2020 Mar 2. doi: 10.1097/QAI.0000000000002309.
    >> Share

    February 2020
  179. GORI A, Antinori A, Vergori A, Cossu MV, et al
    Effectiveness of switching to darunavir/cobicistat in virologically-suppressed HIV-positive patients receiving ritonavir-boosted protease inhibitor-based regimen: the "STORE" Study.
    J Acquir Immune Defic Syndr. 2020 Feb 24. doi: 10.1097/QAI.0000000000002331.
    >> Share

  180. GODFREY C, Hughes MD, Ritz J, Coelho L, et al
    SEX DIFFERENCES IN OUTCOMES FOR INDIVIDUALS PRESENTING FOR THIRD-LINE ANTIRETROVIRAL THERAPY.
    J Acquir Immune Defic Syndr. 2020 Feb 10. doi: 10.1097/QAI.0000000000002324.
    >> Share


  181. Birth Defects After Exposure to Efavirenz-Based Antiretroviral Therapy at Conception/First Trimester of Pregnancy: A Multicohort Analysis: Corrigendum.
    J Acquir Immune Defic Syndr. 2020;83:e15.
    >> Share

  182. AIZIRE J, Brooks KM, Mirochnick M, Flynn PM, et al
    Antenatal Intracellular Concentrations of Tenofovir Diphosphate and Emtricitabine Triphosphate and Associations Between Tenofovir Diphosphate and Severe Adverse Pregnancy Outcomes: IMPAACT-PROMISE (1077BF) Trial.
    J Acquir Immune Defic Syndr. 2020;83:173-180.
    >> Share

  183. HUGHES E, Mwebaza N, Huang L, Kajubi R, et al
    Efavirenz-Based Antiretroviral Therapy Reduces Artemether-Lumefantrine Exposure for Malaria Treatment in HIV-Infected Pregnant Women.
    J Acquir Immune Defic Syndr. 2020;83:140-147.
    >> Share

    January 2020
  184. MERCURIO V, Fitzgerald W, Molodtsov I, Margolis L, et al
    Persistent immune activation in HIV-1 infected ex vivo model tissues subjected to antiretroviral therapy: Soluble and extracellular vesicle-associated cytokines.
    J Acquir Immune Defic Syndr. 2020 Jan 30. doi: 10.1097/QAI.0000000000002301.
    >> Share

  185. ERON J, Hung CC, Baril JG, Slim J, et al
    Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis.
    J Acquir Immune Defic Syndr. 2020 Jan 16. doi: 10.1097/QAI.0000000000002302.
    >> Share

  186. FLAX VL, Kasasa S, Ssendagire S, Lane C, et al
    Using a quality improvement approach in the prevention of mother-to-child HIV transmission program in Uganda improves key outcomes and is sustainable in demonstration facilities: Partnership for HIV-Free Survival.
    J Acquir Immune Defic Syndr. 2020 Jan 13. doi: 10.1097/QAI.0000000000002298.
    >> Share

  187. GREENBERG L, Ryom L, Wandeler G, Grabmeier-Pfistershammer K, et al
    Uptake and discontinuation of integrase inhibitors (INSTIs) in a large cohort setting.
    J Acquir Immune Defic Syndr. 2020 Jan 8. doi: 10.1097/QAI.0000000000002250.
    >> Share

  188. EKE AC, Stek AM, Wang J, Kreitchmann R, et al
    Darunavir pharmacokinetics with an increased dose during pregnancy.
    J Acquir Immune Defic Syndr. 2020 Jan 8. doi: 10.1097/QAI.0000000000002261.
    >> Share

  189. PATEL F, Thurman C, Liberty A, Burke M, et al
    Negative diagnostic PCR tests in school-aged, HIV-infected children on antiretroviral therapy since early life in Johannesburg, South Africa.
    J Acquir Immune Defic Syndr. 2020 Jan 6. doi: 10.1097/QAI.0000000000002265.
    >> Share

  190. CLARKE DF, Acosta EP, Cababasay M, Wang J, et al
    Raltegravir (RAL) in neonates: Dosing, pharmacokinetics (PK), and safety in HIV-1 exposed neonates at risk of infection (IMPAACT P1110).
    J Acquir Immune Defic Syndr. 2020 Jan 6. doi: 10.1097/QAI.0000000000002294.
    >> Share

  191. PATHELA P, Jamison K, Blank S, Daskalakis D, et al
    The HIV Pre-exposure Prophylaxis (PrEP) cascade at NYC Sexual Health Clinics: Navigation is the Key to Uptake.
    J Acquir Immune Defic Syndr. 2020 Jan 3. doi: 10.1097/QAI.0000000000002274.
    >> Share

  192. NORTHROP AJ, Pomeroy LW
    Forecasting Prevalence of HIV-1 Integrase Strand Transfer Inhibitor (INSTI) Drug Resistance: A Modeling Study.
    J Acquir Immune Defic Syndr. 2020;83:65-71.
    >> Share

    December 2019
  193. VAN EPPS P, Wilson BM, Garner W, Beste LA, et al
    Brief Report: Incidence of HIV in a Nationwide Cohort Receiving Pre-exposure Prophylaxis for HIV Prevention.
    J Acquir Immune Defic Syndr. 2019;82:427-430.
    >> Share

  194. CAHN P, Madero JS, Arribas JR, Antinori A, et al
    Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials.
    J Acquir Immune Defic Syndr. 2019 Dec 10. doi: 10.1097/QAI.0000000000002275.
    >> Share

  195. MAYER KH, Allan-Blitz LT
    PrEP 1.0 and Beyond: Optimizing a Biobehavioral Intervention.
    J Acquir Immune Defic Syndr. 2019;82 Suppl 2:S113-S117.
    >> Share

  196. CLARKE DF, Mirochnick M, Acosta EP, Capparelli E, et al
    Use of Modeling and Simulations to Determine Raltegravir Dosing in Neonates: A Model for Safely and Efficiently Determining Appropriate Neonatal Dosing Regimens: IMPAACT P1110.
    J Acquir Immune Defic Syndr. 2019;82:392-398.
    >> Share

    November 2019
  197. KITYO C, Hagins D, Koenig E, Avihingsanon A, et al
    Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial.
    J Acquir Immune Defic Syndr. 2019;82:321-328.
    >> Share

    September 2019
  198. ONYANGO-MAKUMBI C, Owora AH, Mwiru RS, Mwatha A, et al
    EXTENDED PROPHYLAXIS WITH NEVIRAPINE DOES NOT AFFECT GROWTH IN HIV-EXPOSED INFANTS.
    J Acquir Immune Defic Syndr. 2019 Sep 13. doi: 10.1097/QAI.0000000000002145.
    >> Share

    July 2019
  199. MEHROTRA ML, Westreich D, McMahan VM, Glymour MM, et al
    Baseline Characteristics Explain Differences in Effectiveness of Randomization to Daily Oral TDF/FTC PrEP Between Transgender Women and Cisgender Men Who Have Sex With Men in the iPrEx Trial.
    J Acquir Immune Defic Syndr. 2019;81:e94-e98.
    >> Share

    November 2018
  200. FALASCA F, De Vito C, Mazzuti L, di Carlo D, et al
    Copy-Years Viremia and Risk of Virological Failure in Long-Term Treated HIV Patients.
    J Acquir Immune Defic Syndr. 2018 Nov 29. doi: 10.1097/QAI.0000000000001931.
    >> Share

  201. YEN YF, Ko MC, Yen MY, Hu BS, et al
    Human Immunodeficiency Virus Increases the Risk of Incident Heart Failure.
    J Acquir Immune Defic Syndr. 2018 Nov 20. doi: 10.1097/QAI.0000000000001917.
    >> Share

    October 2018
  202. MONTOYA JL, Campbell LM, Paolillo EW, Ellis RJ, et al
    Inflammation Relates to Poorer Complex Motor Performance among Adults Living with HIV on Suppressive Antiretroviral Therapy.
    J Acquir Immune Defic Syndr. 2018 Oct 25. doi: 10.1097/QAI.0000000000001881.
    >> Share

  203. MILAM J, Jain S, Dube MP, Daar ES, et al
    Sexual Risk Compensation in a Pre-exposure Prophylaxis Demonstration Study among Individuals at Risk for HIV.
    J Acquir Immune Defic Syndr. 2018 Oct 10. doi: 10.1097/QAI.0000000000001885.
    >> Share

  204. YEN YF, Feng JY, Yi-Fong Su V, Chuang PH, et al
    Human Immunodeficiency Virus Infection Increases the Risk of Incident Uveitis Among People Living With HIV/AIDS.
    J Acquir Immune Defic Syndr. 2018;79:149-157.
    >> Share

  205. SADOH A, Eki-Udoko FE
    Cotransmission of Malaria and HIV to Infants of Mothers Coinfected With Malaria and HIV in the HAART Era in Benin City, Nigeria.
    J Acquir Immune Defic Syndr. 2018;79:255-260.
    >> Share

    April 2018
  206. SHIAU S, Strehlau R, Shen J, Violari A, et al
    Biomarkers of aging in HIV-infected children on suppressive antiretroviral therapy.
    J Acquir Immune Defic Syndr. 2018 Apr 27. doi: 10.1097/QAI.0000000000001714.
    >> Share

    March 2018
  207. MEIRELES MV, Pascom ARP, Duarte EC
    Factors associated with early virological response in HIV-infected individuals starting antiretroviral therapy in Brazil (2014-2015): results from a large HIV surveillance cohort.
    J Acquir Immune Defic Syndr. 2018 Mar 19. doi: 10.1097/QAI.0000000000001684.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016